The age-adjusted odds ratio for MI was 4.0 (95% confidence study among women ages 18 to 44 years in western Washinterval 1.1 to 15.1). The relative risk was high when another ington, we assessed the relationship between carriership of major cardiovascular risk factor was also present, such as a genetic clotting factor II variant (20210 GrA) and myocarsmoking (odds ratio 43.3, 95% confidence interval 6.7 to 281), dial infarction (MI). The factor II variant was previously and the risk seemed limited to those with other risk factors. shown to be present in 1% to 2% of the population, to inThese results, in which the effect of major coronary risk crease the levels of factor II, and to be associated with vefactors is enhanced fourfold to sixfold by the prothrombin nous thrombotic disease. Personal interviews and blood variant, are similar to those previously reported for another samples were obtained from 79 women with a first myocargenetic clotting abnormality, factor V Leiden. We conclude dial infarction and 381 control women identified through that factor II 20210 G to A increases the risk of myocardial random-digit telephone dialing. Polymerase chain reaction infarction in young women, especially in the women with (PCR) method was used to determine the factor II genotypes.
P
Our previous analyses have demonstrated that besides its ROTHROMBIN (factor II) is the precursor of thrombin, the final effector of the clotting cascade that leads to relevance to public health in young women, our study also the formation of fibrin. Prothrombin is a key enzyme in the provides a model for studying the interaction of atherogenic balance between procoagulation and anticoagulation because and thrombogenic risk factors. 8-10 Therefore, we set out to it potentiates coagulation by positive feedback loops and assess the effect of a newly described prothrombotic genetic also promotes anticoagulation by the protein C pathway. 1, 2 abnormality, the prothombin 20210 G to A transition. This A recently described genetic variant of prothrombin is is a fairly common variant and thus of potential importance associated with an increased risk of venous thrombosis. 3 The in the etiology of myocardial infarction. variant is located in the 3-untranslated region of the gene (on chromosome 11), at position 20210, 4 where one nucleotide is
MATERIALS AND METHODS

changed (a G to A transition). Carriership of this variant is
We conducted a population-based case-control study of myocarassociated with elevated levels of prothrombin in plasma, dial infarction among women 18 to 44 years of age residing in three which are related to an increased risk of thrombosis. Among contiguous counties of western Washington state. The methods of 474 patients with a first deep-vein thrombosis we found the the study have been described extensively previously. 8, 11 Cases were women aged 18 to 44, without a prior history of coronary heart 20210 G r A variant in 6.2%, as opposed to 2.3% among disease or cerebrovascular disease, who were diagnosed between 471 healthy control subjects. From these results we con- July 1, 1991 and February 28, 1995 is a genetic cause of thrombosis. In a second sample of 646
Controls were identified by random-digit telephone dialing. Eligiunaffected individuals, we found the mutation in 1%, which ble were women aged 18 to 44 years living in the same area during led us to the conclusion that the prevalence in The Netherthe time period of the study without a history of cardiovascular lands is 1% to 2%.
5
Recently we have shown that another common genetic abnormality, a mutation in clotting factor V that causes resis- women, and 9.5% of women who suffered an MI at a young Submitted June 3, 1997; accepted June 13, 1997. age. ORs are adjusted for age, and calculated separately for each stratum with a dummy variable model, age-adjusted and relative to the referble angina and were excluded from this analysis). The technician who performed DNA analyses was blinded as to whether a specimen ence category (OR 1). Metabolic risk factors are either obesity or a physician's diagnosis of diabetes mellitus, hyeprtension, or hyperchowas from a patient or a control subject.
The presence of the factor II variant (20210, G to A replacement)
lesterolemia.
was first determined using an A-allele-specific polymerase chain reaction (PCR) according to the method of Glisic and Alavantic.
15
The heterozygous AG-status of putative positives was confirmed by was examined by unconditional logistic regression adjusted for the the presence of a HindIII restriction site in the relevant PCR-fragmatching variable age, and expressed with the odds ratio (OR) as a ment using a previously described protocol. 3 measure for relative risk. Effect modification was assessed through Smokers were defined as women who reported smoking currently stratified analyses. Confidence intervals (95%, CI95) were calculated and regularly, while all others were classified as nonsmokers. A by standard methodology. woman was classified as diabetic, hypertensive, or hypercholesterolemic if she reported that she had ever been diagnosed by a physician RESULTS as such. Additionally, we assessed which women were currently taking prescription drugs for these conditions. We considered obese
The 79 women with an acute MI had a mean age of 39.7 any woman with a body mass index (BMI) equal to or exceeding (median 41), the control women of 37.7 (median 39.0). All 27.3 kg/m 2 . In some analyses the variables for hypertension, hypermajor risk factors for coronary disease such as smoking, cholesterolemia, diabetes mellitus, and obesity were grouped toobesity, hypertension, hypercholesterolemia, and diabetes gether as 'metabolic risk factors. ' were reported more often among cases than among controls
The association of carriership of the factor II variant with MI (Table 1) . Smoking (75%) and obesity (58%) were particularly prevalent among the patients. control women (6 of 381) ( Table 2 ). All carriers of the mutation were white women whereas none of the 51 non-
white women in the study carried the mutation. The OR for few women to allow risk estimation.
Currently drug-treated for
The risk associated with factor II 20210A was particularly and that therefore even small absolute risks contribute significantly to overall morbidity and mortality among the young. The factor V Leiden mutation has a distinct racial and, to tes mellitus) the risk was increased 34-fold (CI95 5.5 to 209) a lesser extent, geographical distribution. 21, 22 It is common when they carried the factor II variant. In contrast, women in Caucasians and very rare in Asians and Africans; among with one or more of these metabolic risk factors without the Caucasians in Europe, there seems to be a North-South factor II variant had a 5.3-fold increased risk (CI95 2.9 to gradient, with prevalences ranging between 2% in Italy to 9.9); ie, the already elevated risk among women with these 7% in Sweden. Among 51 nonwhite women in this study, risk factors was increased further by more than sixfold. Rewe did not find any carriers of the factor II mutation. Because striction of this analysis to drug-treated hypertension, hyperthe overall prevalence of the factor II mutation was 1.6%, cholesterolemia, or diabetes mellitus (instead of reported this is obviously well within the expected finding; neverthephysician's diagnosis of these conditions) led to similar reless, our data suggest the possibility that this variant, like the sults.
factor V Leiden mutation, is also present mainly in whites. These results of a striking synergy with other major car-
The findings of an association of MI with factor II 20210 diovascular risk factors is similar to what we have previously G to A only among young women with other risk factors described for the association of factor V Leiden (factor V are strikingly similar to our previous reports on factor V 1691 G to A) and MI among these young women. Therefore, Leiden in young women. 8 Both clotting abormalities display we combined these two mutations into one variable reprea strong synergistic effect with other cardiovascular risk facsenting either clotting abnormality, which was present in 12 tors, in particular with smoking. These two recently discovcases (15.2%) and 21 controls (5.5%). None of the 460 ered clotting abnormalities were present in over 5% of the women carried the combination of factor V Leiden and factor population, and thus may affect a large number of people. II 20210A (located on chromosome 1 and 11, respectively).
In young women, MI appears to be the result of combined The OR associated with any clotting abnormality was 3.1, atherogenic and thrombogenic factors. Without a concomitwith a 95% confidence interval of 1.5 to 6.7 (P Å .003). tant atherogenic abnormality, there was little effect of the This relative risk indicates a moderate strength risk factor clotting abnormality with regard to the risk of MI. The rethat increases the risk threefold; however, when the clotting verse seemed true, too, as is shown in Table 3 : the various abnormality was present combined with other cardiovascular atherogenic risk factors, such as obesity, hypercholesterolrisk factors, the relative risks ranged from 21 (obesity) to emia, hypertension, and diabetes had a modest effect on the 36 (smoking), compared to women without the other risk risk of MI in these women when present solely; and this risk factor or any clotting abnormality. Table 3 shows the relative was greatly enhanced when a clotting abnormality as factor risks of several major determinants of coronary disease when V Leiden or factor II 20210A was simultaneously present. present without the clotting abnormality, and when present Our results are based on a small number of mutant gene in combination with the clotting abnormality. The presence carriers and therefore the statistical uncertainty around the of either prothrombotic mutation (factor V Leiden or factor risk estimates remained considerable. The confidence inter-II 20210A) increased further the already elevated risk of MI vals were particularly wide for the estimates in the interacassociated with smoking, obesity, and metabolic risk factors tion analysis. However, because the results for the overall by fourfold to sixfold.
effects of carriership of factor II 20210 A, as well as for the interaction with other major risk factors for coronary disease,
DISCUSSION
are similar to those we reported previously for factor V Leiden, we feel confident about our conclusions of an in-A common variant in the prothrombin gene, factor II creased risk and synergism with other risk factors. Although 20210 G to A replacement, was associated with an overall fourfold increased risk of MI in young women. with MI at a young age, a similar effect of another clotting Risk factors and natural history. Am Heart J 105:548, 1983 abnormality (factor V Leiden). aged and older adults, they may differ in their strengths. 19,20,23 Coll Cardiol 26:654, 1995 Therefore, our findings cannot be generalized to older or while to look for specific interactions of risk factors in those 1:263, 1991 populations as well.
